intruder test, reflects decreased aggressive motivation. Behavioral changes in recipients were accompanied with cytokines brain changes: decreased IL-1β, IL-2, IL-6, INFγ in the hippocampus; increased IL-4 and decreased INFγ in the hypothalamus; decreased IL-1β in the frontal cortex.

Conclusions: Chlorpromazine - modulated immune cells have a positive aggressive behavior editing effect being involved in the central mechanisms underlying the development of aggressive reactions.

Disclosure: No significant relationships.

Keywords: aggression; immune cells

O0089
Clinical, genetic and environmental influences on weight gain and metabolic disorders induced by psychotropic drugs
C. Eap
Center for Psychiatric Neurosciences, Department Of Psychiatry, Prilly-Lausanne, Switzerland
doi: 10.1192/j.eurpsy.2022.280

Introduction: Weight gain and obesity are important health problems associated with psychiatric disorders and/or with psychotropic drug treatments. There is a high inter-individual variability in the susceptibility to drug induced weight gain and/or other cardiometabolic disorders.

Objectives: To study the genetic and environmental risk factors for weight gain and onset of metabolic syndrome during psychotropic treatment

Methods: Analysis in PsyMetab, a large (n>3000) ongoing longitudinal prospective cohort study investigating cardiometabolic disorders in psychiatric patients.

Results: Aside from well-known clinical risk factors for metabolic worsening (e.g. young age, first episode status, rapid weight gain during the first month of treatment and/or low initial BMI), additional risk factors have been recently identified. We showed an inverse association between socio-economic status (SES) and worsening of cardiometabolic parameters, adult patients with a low SES having a three-fold higher risk of developing metabolic syndrome over one year versus patients with a high SES (n=366). In addition, a causal inverse effect of educational attainment on BMI was revealed using Mendelian randomization in the UKBiobank (n=30'069). Results from an epigenome-wide association study (EWAS) performed in 78 patients before and after one month of treatment and from a genome-wide association study (GWAS) in 1924 patients will also be presented.

Conclusions: Differences in clinical, genetic and environmental factors contribute to the differences in weight gain and metabolic disorders induced by psychotropic drugs. When starting a psychotropic drug at risk, a prospective monitoring of clinical (e.g. weight and blood pressure) and biochemical (fasting glucose, lipid levels) parameters is essential.

Disclosure: Prof. Eap received honoraria for conferences or teaching CME courses from Janssen-Cilag, Lundbeck, Otsuka, Sandoz, Servier, Sunovion, Vifor-Pharma, and Zeller in the past 3 years. The other authors report no potential conflicts of interest. This work has

Keywords: Genetics; metabolic syndrome; psychotropic drugs; epigenetics

O0090
Comparative efficacy and safety of escitalopram, desvenlafaxine, and vortioxetine in the acute treatment of anxious depression: A randomized rater-blinded, 6-week clinical trial
K.-S. Oh1* and S.W. Jeon2
1Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Department Of Psych, Seoul, Korea, Republic of and 2Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Department Of Psychiatry, Seoul, Korea, Republic of

*Corresponding author.
doi: 10.1192/j.eurpsy.2022.281

Introduction: Anxiety and depressive symptoms are frequent co-occurring phenomena. Several studies have reported that psychotropic drugs can induce a depressive/anxiety state in patients with anxiety disorders or other psychiatric disorders. However, the efficacy of antidepressant drugs has been controversial in patients with anxious depression. objective: To compare the efficacy of escitalopram, desvenlafaxine, and vortioxetine in the acute treatment of anxious depression.

Methods: A 6-week clinical trial design with an open-label, single-blind, parallel-group, randomized design was used. Patients were randomized to treatment with escitalopram (n=161), desvenlafaxine (n=162), or vortioxetine (n=163). The primary outcome measure was the Montgomery-Asberg Depression Rating Scale (MADRS) and anxiety scale (ShARS Scale). The hormonal and monoamines levels in the serum blood were measured by ELISA tests before and after SSRIs therapy.

Results: After 6 months of SSRIs therapy, MADRS Scale showed an incomplete disappearance of the depressive/anxiety manifestations in both men and women with the clinically confirmed MDD case after COVID-19 (p<0.05). We found that SSRIs were able to reduce depression/anxiety levels only on 20% in man or on 30% in women with the initial MDD case after COVID-19 before treatment.

Conclusions: SSRIs treatment alone failed to produce the decrease of depression/anxiety in the patients of both gender with the initial MDD or GAD diagnosis after COVID-19. The further randomized clinical trials involving new pharmacological therapies for psychiatric patients after COVID-19 disease are needed.

Disclosure: No significant relationships.

Keywords: Covid-19; depression; anxiety; SSRIs; psychotherapy